Syndax Pharmaceuticals SNDX Restricted Cash
Restricted Cash at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCashNoncurrent.
The official record: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Syndax Pharmaceuticals's restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Syndax Pharmaceuticals's restricted cash?
- Syndax Pharmaceuticals (SNDX) reported restricted cash of $102K in Q1 2026.
- How has Syndax Pharmaceuticals's restricted cash changed year-over-year?
- Syndax Pharmaceuticals's restricted cash decreased by 53.0% year-over-year, from $217K to $102K.
- What is the long-term trend for Syndax Pharmaceuticals's restricted cash?
- Over 5 years (2020 to 2025), Syndax Pharmaceuticals's restricted cash has grown at a -2.4% compound annual growth rate (CAGR), from $115K to $102K.
- What does restricted cash mean?
- Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.